French femtech firm Fizimed raises €4m to expand pelvic health devices and breast pumps internationally
Fizimed, a French femtech company specialising in women’s health technology, has secured €4 million in funding to accelerate its international expansion. The financing round was led by the Autonomous Patient Fund, managed by Bpifrance, alongside insurance group UNIQA and private equity firm UI Investissement.
The Strasbourg-based company, founded in 2017, has gained recognition for its innovative medical devices aimed at addressing under-discussed women’s health issues, including pelvic floor disorders and breastfeeding challenges. Among its flagship products is the Emy Trainer, a pelvic floor rehabilitation device designed to help women strengthen their pelvic muscles at home through an app-based system. The company also produces the Emy Pump, a hands-free breast pump aimed at simplifying breastfeeding for new mothers.
“This fundraising is a key moment in Fizimed’s history,” said Emeline Hahn, CEO of Fizimed.
“It will allow us to help an even greater number of women internationally and offer them concrete and effective solutions to improve their quality of life.”
International expansion
The latest funding round will help the firm expand into international markets, particularly in German-speaking countries and the United States. Fizimed has already established a presence in Germany, where its pelvic floor trainer is covered by the country’s social security system.
Jean-Briac Lesné, Investment Director at Bpifrance, welcomed the opportunity to support the company’s growth.
“We are very pleased to support the international expansion of Fizimed, a pioneering French company in the field of femtech, which has already proven the effectiveness of its solutions and their positive impact on the lives of many women,” he said.
Fizimed’s expansion strategy includes strengthening its partnerships with healthcare professionals, increasing public awareness of its products, and further developing its technology. The company also emphasises its commitment to sustainable manufacturing, with a focus on using materials sourced in France to minimise its carbon footprint.
“As a major player in femtech in Europe, Fizimed’s technology paves the way for a lasting impact on women’s health across the continent,” said Aurélia Bojmal, Investment Director at UI Investissement.
The investment round also saw continued support from Capital Grand Est, which has backed Fizimed since 2018. Jean-François Rax, Associate Director at Capital Grand Est, reaffirmed the firm’s confidence in the company’s potential:
“We are very pleased to continue our support for Fizimed. We look forward to working alongside the Autonomous Patient Fund, UNIQA and UI Investissement to give Fizimed the means to expand on the European continent and become a key player in women’s health.”
The investment round of Fizimed comes in the same month that FemTech pioneer Elvie, which also produced wearable breast pumps and pelvic health devices, was acquired by US-firm Willow.